APA (7th ed.) Citation

Sim, V., Forner, S., Burcombe, R., & Glendenning, J. (2019). The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience. Clinical Oncology, 31(7), e114. https://doi.org/10.1016/j.clon.2019.03.034

Chicago Style (17th ed.) Citation

Sim, V., S. Forner, R. Burcombe, and J. Glendenning. "The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience." Clinical Oncology 31, no. 7 (2019): e114. https://doi.org/10.1016/j.clon.2019.03.034.

MLA (9th ed.) Citation

Sim, V., et al. "The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience." Clinical Oncology, vol. 31, no. 7, 2019, p. e114, https://doi.org/10.1016/j.clon.2019.03.034.